ArticleMethods in molecular biology (Clifton, N.J.)2027
Deep Learning Protocols for Predicting Drug Mechanism of Action and Drug-Target Interactions.
Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding drug mechanisms of action (MOA) and predicting drug-target interactions (DTIs) are fundamental challenges in modern drug discovery and development, hindered by high costs, long development timelines, and limited knowledge of compound activity and molecular targets. Here, we present two deep learning-based computational protocols designed to address these challenges. The first framework employs directed message passing neural networks (D-MPNN) to predict drug MOA from chemical-genetic interaction profiles (CGIPs), by learning how molecular structures perturb biological pathways through systematic profiling across genetically sensitized strains. The second framework, iNGNN-DTI, utilizes interpretable nested graph neural networks combined with pretrained molecule models to predict DTIs, leveraging cross-attention mechanisms to provide insights into binding determinants. We highlight the application of these methods to key therapeutic areas, including antibacterial drug discovery and drug repurposing for COVID-19 therapeutics. Each protocol provides comprehensive guidance on data preparation, model implementation, validation strategies, and result analysis. These computational approaches offer scalable, cost-effective tools for accelerating therapeutic development by bridging chemical structure, molecular interactions, and systems-level biological responses.
Indexed as
Identifiers
42734743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.